[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"oocyte-maturation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:oocyte-maturation":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,56,91],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100628788","phase-4-exogenous-progesterone-as-ovulation-trigger-100628788",false,"NCT07466199","Exogenous Progesterone as Ovulation Trigger","Exogenous Progesterone as Ovulation Trigger - a Pilot Study","PRO-TRIGGER","Inclusion Criteria:\n\n* Informed Consent Form dated and signed correctly prior to the performance of any study procedure.\n* Oocyte donors aged \\>17 and \\\u003C34 years old in the moment of the recruitment.\n* Patients with regular menstrual cycles (between 25 to 35 days long).\n* Generally healthy women with no history of endocrine disorders (e.g., polycystic ovary syndrome (PCOS) or significant systemic disease).\n* Body Mass Index (BMI) between 18.5 and 28.\n\nExclusion Criteria:\n\n* Presence of ovarian cyst(s) detected on the baseline (initial) ultrasound examination.\n* Untreated endocrine conditions (polycystic ovary syndrome (PCOS), uncontrolled thyroid dysfunction and hyperprolactinemia).\n* Hypogonadotropic or hypergonadotropic hypogonadism.\n* Known hypersensitivity or clinical contraindication to the administration of vaginal progesterone or its excipients. This includes, but is not limited to: active deep vein thrombosis or thromboembolic disorders, known or suspected estrogen- or progesterone-dependent neoplasia, undiagnosed abnormal genital bleeding, porphyria, or severe hepatic dysfunction. Additionally, patients with anatomical abnormalities of the vagina that preclude the proper insertion or absorption of the vaginal insert are excluded.\n* Any condition contraindicating vaginal ultrasound and\u002For vaginal oocyte retrieval.These include: active pelvic inflammatory disease (PID), acute vaginal or cervical infection, or presence of pelvic malignancies. Patients with significant anatomical distortions or vascular anomalies in the pelvic region that, in the investigator's opinion, would make oocyte retrieval technically unfeasible or pose an unacceptable risk of hemorrhage or injury to adjacent organs, are also excluded.\n* Use of hormonal contraceptives (oral, patch, or ring) or GnRH analogues within the month preceding the study. Note: Participants who have discontinued these or other prohibited medications for a period of at least 30 days are eligible for rescreening starting at Visit 1.\n* Participation in any other ongoing clinical trial or use of investigational drugs within the last 30 days.","FEMALE","18 Years","33 Years",{"count":21,"type":22},10,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","The goal of this clinical trial is to learn whether the sudden administration of vaginal micronized progesterone during the late follicular phase can trigger an LH surge and reactivation of oocyte meiosis in healthy oocyte donors aged 18 to 33 undergoing a mild ovarian stimulation cycle. The main question it aims to answer is:\n\n* Does progesterone administered in the late follicular phase induce an LH surge and subsequent oocyte meiosis reactivation?\n\nParticipants will:\n\n* Undergo a mild ovarian stimulation with 75 IU of follitropn alfa\n* Start vaginal micronized progesterone (400 mg every 12 hours) once at least one follicle reaches 15 mm\n* Have blood samples collected to measure hormone levels before and after progesterone administration\n* Undergo oocyte retrieval 35-36 hours after the progesterone trigger\n\nThis is a low-intervention, single-center pilot study including approximately 10 oocyte donors.",[28,29,30,31,32],"Ovulation","Ovarian Function","Assisted Reproductive Treatments","Oocyte Maturation","Hormonal Response",[34,35,36,31,37,38,39,40,41,42],"Trigger","Oocyte Donation","Progesterone","Luteinizing Hormone","LH Surge","Oocyte Retrieval","Oocyte Meiosis","Late Follicular Phase","Endocrinological profile","NOT_YET_RECRUITING","2026-06-02",{"date":46,"type":47},"2026-06-04","ACTUAL",{"date":49,"type":22},"2026-07",{"date":51,"type":22},"2026-08",{"name":53,"class":54},"Instituto Valenciano de Infertilidade de Lisboa","NETWORK",1,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":64,"enrollmentInfo":65,"targetDuration":4,"studyType":23,"phases":67,"briefSummary":69,"conditions":70,"keywords":72,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":55},"100635951","osc-co-culture-for-rescue-ivm-of-human-gv-oocytes-100635951","NCT07559357","OSC Co-culture for Rescue IVM of Human GV Oocytes","Effect of iPSC-Derived Ovarian Support Cell Co-culture on Rescue In Vitro Maturation of Human Germinal Vesicle Oocytes: A Randomized Sibling-Oocyte Controlled Trial","OSC-rIVM","Inclusion Criteria:\n\n* Women aged 18 to 45 years.\n* At least 2 GV oocytes retrieved in a single oocyte retrieval cycle.\n* Voluntary informed consent from the couple to participate in the study.\n* Agreement that all embryos generated from the study will be used for research purposes only and will not be transferred for clinical treatment.\n\nExclusion Criteria:\n\n* Sperm obtained through surgical retrieval procedures, including PESA, MESA, TESE, or micro-TESE.\n* Use of donor gametes, including donor oocytes or donor sperm.\n* Participants with GV oocytes showing obvious morphological abnormalities, such as degeneration, severe deformation, or marked cytoplasmic abnormalities.","45 Years",{"count":66,"type":22},102,[68],"NA","This single-center randomized sibling-oocyte controlled trial evaluates whether co-culture with induced pluripotent stem cell (iPSC)-derived ovarian support cells (OSCs) improves rescue in vitro maturation (r-IVM) outcomes of surplus germinal vesicle (GV) oocytes collected during routine IVF treatment. Eligible GV oocytes from each enrolled participant are allocated within participant in a 1:1 ratio to either conventional r-IVM or r-IVM with OSC co-culture. The primary outcome is the metaphase II (MII) maturation rate after 24 hours of culture. Secondary outcomes include fertilization rate, day 3 embryo formation, good-quality day 3 embryo rate, blastocyst formation, and good-quality blastocyst rate. All embryos generated in the study are for research purposes only and will not be used for clinical embryo transfer.",[31,71],"Infertility",[73,74,75,76,77,78,79,80],"Rescue in vitro maturation","r-IVM","Germinal vesicle oocyte","iPSC-derived ovarian support cells","OSC co-culture","Embryo development","IVF","Sibling-oocyte trial","2026-04-23",{"date":83,"type":47},"2026-04-30",{"date":85,"type":22},"2026-06",{"date":87,"type":22},"2027-05",{"name":89,"class":90},"Hung Vuong Hospital","OTHER",{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":98,"sex":17,"minAge":99,"maxAge":64,"enrollmentInfo":100,"targetDuration":4,"studyType":102,"phases":4,"briefSummary":103,"conditions":104,"keywords":105,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":115,"locationsCount":55},"100391890","follicular-fluid-exosome-mirna-during-oocyte-maturation-100391890","NCT04382872","Follicular Fluid Exosome miRNA During Oocyte Maturation","Investigation of Follicular Fluid Exosome miRNA in Young and Aged Women During Oocyte Maturation","Inclusion Criteria:\n\n1. Women aged 20 to 45;\n2. BMI \\> 19 \\& \\\u003C 35;\n3. Women who is planning to perform invitro fertilization (IVF) together with intracytoplasmic sperm injection (ICSI) for their fertility problems\n\nExclusion Criteria:\n\n1. Positive pregnancy test before taking study medications;\n2. Women with BMI\\>35 kg\u002Fm2;\n3. Women with known chromosomal translocation, recurrent abortions or those carrying Fragile X;\n4. Women with endometriosis",true,"20 Years",{"count":101,"type":22},60,"OBSERVATIONAL","Folliculogenesis involves the recruitment of primordial follicles into a group of growing follicles in which eventually one follicle is selected, matured and ovulated. Complex endocrine and intra-ovarian paracrine interactions occur to create a changing intra-follicular hormonal milieu suitable for oocyte development. However, this oocyte developmental competence and to undergo fertilization and embryogenesis is impaired in aged women. Diminished ovarian function is generally attributed to decreased quantity and quality of oocytes and their surrounding granulosa cells during ovarian aging, although the underlying mechanisms remain unclear.\n\nThe aim of the study is to investigate the miRNA in (follicular fluid) FF exosome in young and aged women and their relationship to egg maturation.",[31],[106,107],"oocyte maturation","in vitro maturation","RECRUITING","2025-08-12",{"date":111,"type":47},"2025-08-13",{"date":113,"type":47},"2021-04-30",{"date":83,"type":22},{"name":116,"class":90},"Chinese University of Hong Kong"]